Transmission of MERS-Coronavirus in Household Contacts by Drosten, C et al.
original article
Th e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 371;9 nejm.org august 28, 2014828
Transmission of MERS-Coronavirus  
in Household Contacts
Christian Drosten, M.D., Benjamin Meyer, M.Sc., Marcel A. Müller, Ph.D.,  
Victor M. Corman, M.D., Malak Al-Masri, R.N., Raheela Hossain, M.D.,  
Hosam Madani, M.Sc., Andrea Sieberg, B.Sc., Berend Jan Bosch, Ph.D.,  
Erik Lattwein, Ph.D., Raafat F. Alhakeem, M.D., Adbullah M. Assiri, M.D.,  
Waleed Hajomar, M.Sc., Ali M. Albarrak, M.D., Jaffar A. Al-Tawfiq, M.D., 
Alimuddin I. Zumla, M.D., and Ziad A. Memish, M.D.
From the Institute of Virology, University 
of Bonn Medical Center, Bonn (C.D., B.M., 
M.A.M., V.M.C., A.S.), and Euroimmun 
AG, Lübeck (E.L.) — both in Germany; 
Global Center for Mass Gatherings 
Medicine, Ministry of Health (M.A.-M., 
R.F.A., A.M. Assiri, A.I.Z., Z.A.M.), Prince 
Sultan Military Medical City (A.M. Al-
barrak), and Alfaisal University (Z.A.M.), 
Riyadh, Johns Hopkins Aramco Health-
care, Dhahran (J.A.A.-T.), and Regional 
Laboratory, Ministry of Health, Jeddah 
(R.H., H.M.) and Riyadh (W.H.) — all in 
Saudi Arabia; Indiana University School 
of Medicine, Indianapolis ( J.A.A.-T.); the 
Department of Infectious Diseases and 
Immunology, Faculty of Veterinary Med-
icine, Utrecht University, Utrecht, the 
Netherlands (B.J.B.); and the Division of 
Infection and Immunity, University Col-
lege London (UCL), and National Insti-
tute for Health Research Biomedical Re-
search Centre, UCL Hospitals, London 
(A.I.Z.). Address reprint requests to Dr. 
Memish at Alfaisal University, P.O. Box 
54146, Riyadh 11514, Saudi Arabia, or at 
zmemish@yahoo.com, or to Dr. Drosten 
at the Institute of Virology, University of 
Bonn Medical Center, 53105 Bonn, Ger-
many, or at drosten@virology-bonn.de.
N Engl J Med 2014;371:828-35.
DOI: 10.1056/NEJMoa1405858
Copyright © 2014 Massachusetts Medical Society.
A bs tr ac t
Background
Strategies to contain the Middle East respiratory syndrome coronavirus (MERS-CoV) 
depend on knowledge of the rate of human-to-human transmission, including sub-
clinical infections. A lack of serologic tools has hindered targeted studies of trans-
mission.
Methods
We studied 26 index patients with MERS-CoV infection and their 280 household 
contacts. The median time from the onset of symptoms in index patients to the latest 
blood sampling in contact patients was 17.5 days (range, 5 to 216; mean, 34.4). 
Probable cases of secondary transmission were identified on the basis of reactivity 
in two reverse-transcriptase–polymerase-chain-reaction (RT-PCR) assays with inde-
pendent RNA extraction from throat swabs or reactivity on enzyme-linked immuno-
sorbent assay against MERS-CoV S1 antigen, supported by reactivity on recombinant 
S-protein immunofluorescence and demonstration of neutralization of more than 
50% of the infectious virus seed dose on plaque-reduction neutralization testing.
Results
Among the 280 household contacts of the 26 index patients, there were 12 probable 
cases of secondary transmission (4%; 95% confidence interval, 2 to 7). Of these 
cases, 7 were identified by means of RT-PCR, all in samples obtained within 14 days 
after the onset of symptoms in index patients, and 5 were identified by means of 
serologic analysis, all in samples obtained 13 days or more after symptom onset in 
index patients. Probable cases of secondary transmission occurred in 6 of 26 clus-
ters (23%). Serologic results in contacts who were sampled 13 days or more after 
exposure were similar to overall study results for combined RT-PCR and serologic 
testing.
Conclusions
The rate of secondary transmission among household contacts of patients with 
MERS-CoV infection is low. Our data provide insight into the rate of subclinical 
transmission of MERS-CoV in the home.
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The Middle East respiratory syn-drome coronavirus (MERS-CoV) was first isolated in 2012 from a patient with fatal 
pneumonia in Jeddah, Saudi Arabia.1 From 2012 
through July 2014, at least 834 laboratory-con-
firmed cases of MERS-CoV infection associated 
mostly with respiratory tract illness were report-
ed to the World Health Organization; of these 
cases, 288 were fatal. Known cases have been 
directly or indirectly linked to countries in the 
Arabian peninsula.2 The epidemiologic features 
of MERS remain poorly defined. Studies that 
have modeled the reproductive rate of MERS-CoV 
in humans have been based on notified, clinically 
apparent cases and auxiliary measurements, such 
as the viral evolutionary rate.3,4 However, these 
studies have emphasized the need to reevaluate 
estimates of reproductive rates through labora-
tory-based investigations of the actual rate of 
transmission, including silent and subclinical 
infections. Any unnoticed transmission of the 
virus in the population could explain why newly 
identified index cases often cannot be linked to 
zoonotic exposure. However, to date, the lack of 
serologic tools has hindered in-depth investiga-
tion of rates of secondary transmission.
To determine the rate of silent or subclinical 
secondary infection after exposure to primary 
cases of MERS-CoV infection, we performed a 
cross-sectional laboratory investigation of 280 
household contacts of 26 index patients, with ad-
ditional follow-up serologic analysis in 44 con-
tacts. All the contacts were tested for the pres-
ence and quantity of viral RNA in throat-swab 
samples and for antibodies in blood with the use 
of a staged serologic algorithm that is based on 
results from enzyme-linked immunosorbent 
assays (ELISAs), immunofluorescence assays, and 
plaque-reduction neutralization testing (PRNT).
Me thods
Patients
Household contact clusters were associated with 
the 26 index patients in whom MERS-CoV infec-
tion was diagnosed from June 4, 2013, to Novem-
ber 5, 2013, with one cluster per index patient. 
The median date on which clusters were sampled 
was September 8, 2013. Diagnoses in index pa-
tients were based on hospitalization with bilateral 
pneumonia and detection of MERS-CoV in respi-
ratory samples on reverse-transcriptase–polymer-
ase chain reaction (RT-PCR). All household con-
tacts of index patients (who were defined as 
persons living in the same house, regardless of 
the degree of relation to the index patient) were 
obliged to participate in the investigation per de-
cree of the Ministry of Health as part of a public 
health response. Clusters occurred in Riyadh 
(16 clusters), Eastern Province (3), Al-Hasa (2), 
Hafr Al-Batin (2), Jubail (2), and Jeddah (1).
MERS-CoV RT-PCR Assay
We performed RT-PCR assays on RNA that was 
extracted from upper respiratory tract swabs, with 
screening for the MERS-CoV genomic region up-
stream of the envelope gene (upE) and within 
open reading frame (ORF) 1a, as described pre-
viously.5,6 Confirmation of upE results by ORF1a 
detection involved the reextraction of RNA from 
the original samples.
Full-Virus Immunofluorescence Assay
Immunofluorescence assays were performed with 
slides carrying Vero cells infected with full 
MERS-CoV, as described previously,6 and were 
manufactured into a homogeneous reagent for-
mat by an in vitro diagnostics company for im-
proved lot-to-lot consistency (MERS IIFT, Euro-
immun). The serum predilution was 1:100.
Recombinant Immunofluorescence Assay
We performed recombinant immunofluorescence 
assays to determine the specific reactivity 
against recombinant spike proteins in VeroB4 
cells, as described previously.6 The screening di-
lution was 1:40. Because the CoV spike protein 
constitutes the most specific and immunogenic 
antigen in CoV antibody assays,7 open reading 
frames for full spike proteins were cloned from 
human coronaviruses (HCoV) HCoV-229E, HCoV-
NL63, HCoV-OC43, and HCoV-HKU1, as well as 
for the severe acute respiratory syndrome corona-
virus (SARS-CoV).6,8 Cells for all slides were 
seeded on chamber slides and transfected in par-
allel with equal amounts of the respective ex-
pression plasmids.6,8 To compare titers for 
MERS-CoV with those for different HCoVs, im-
munofluorescence assays were performed by the 
same staff member on the same day. Control se-
rum samples for HCoV recombinant immuno-
fluorescence assays were obtained from patients 
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with recent RT-PCR–confirmed HCoV-229E, 
HCoV-NL63, HCoV-OC43, or HCoV-HKU1 infec-
tion, as seen in routine diagnostic testing. The 
methods for obtaining control serum samples 
for testing for the presence of MERS-CoV and 
SARS-CoV have been described previously.6,8-10
IgM Immunofluorescence Assay
Immunofluorescence assay was used to determine 
the presence of IgM antibodies. All serum samples 
were depleted of IgG antibodies with the use of 
Eurosorb reagent (Euroimmun), according to the 
protocol. The screening dilution was 1:40. Second-
ary detection was performed with the use of flu-
orescein isothiocyanate (FITC)–conjugated anti-
human IgM antibodies.
Recombinant ELISA
A recombinant ELISA assay was based on soluble 
MERS-CoV spike protein S1 domain expressed in 
HEK-293T cells.11 This test was developed with the 
use of samples obtained from small groups of 
humans and camels in preliminary studies.7,12 The 
dilution of human serum samples in this test was 
1:100. Additional technical details are provided in 
Section 1 in the Supplementary Appendix, avail-
able with the full text of this article at NEJM.org.
Neutralization Testing
PRNT was performed as described previously.8 
The entry dilution in log2-dilution series was 1:10. 
Serum dilutions causing plaque reductions of 
90% (PRNT90) and 50% (PRNT50) were recorded 
as titers.
Diagnostic Algorithm to Identify Secondary 
Transmission
We used the above-mentioned RT-PCR method to 
screen for MERS-CoV in throat swabs. Serum 
samples were initially screened for antibodies by 
means of an ELISA. Supportive serologic testing 
was performed in two stages. Stage 1 seroposi-
tivity was defined as reactivity on both an ELISA 
and a recombinant immunofluorescence assay. 
Stage 2 seropositivity was defined as stage 1 sero-
positivity plus reactivity on PRNT. Patients who 
had dual positive RT-PCR results or positive stage 
2 serologic results were determined to have prob-
able cases of secondary transmission. A flow 
chart summarizing the diagnostic algorithm and 
overall study outcome is provided in Figure 1.
R esult s
Study Population
The household clusters we studied included a 
mean of 11 contacts (range, 2 to 21). The median 
age of the 26 index patients was 55 years (range, 
2 to 83; mean, 54.6); 17 of the patients were male. 
Of these patients, 24 had coexisting illnesses, 24 
required treatment in an intensive care unit, and 
18 died. Index patients had stayed at home with 
symptoms before hospital admission for an aver-
age of 6 days (range, 0 to 21). The median age of 
the 280 household contacts was 29 years (range, 
2 to 77; mean, 30.7); 48% of these contacts were 
female. A total of 59 household contacts were 16 
years of age or younger.
The median interval from the onset of symp-
toms in index patients to the collection of the 
latest blood sample from household contacts was 
17.5 days (range, 5 to 216; mean, 34.4). Information 
with respect to coexisting illnesses was recorded 
for 178 household contacts; of these contacts, 
12% had coexisting illnesses (Table S1 in the 
Supplementary Appendix).
Laboratory Testing
Throat swabs from all household contacts were 
initially tested for MERS-CoV RNA by means of 
RT-PCR. Of the 280 contacts, 7 (2%) who lived in 
three clusters had dual positive results on RT-PCR 
(Fig. 1A). Virus RNA levels in swabs obtained 
from these contacts ranged from fewer than 500 
copies to 80,000 copies per swab sample, with a 
median level of 2700 copies per sample (Table 1). 
Only 1 contact with positive results on RT-PCR 
had mild symptoms at the time of sampling, and 
2 contacts had had contact with camels, which 
have been identified as possible reservoirs for 
MERS-CoV.12
Serologic testing was based on a staged algo-
rithm (Fig. 1B). The algorithm was established 
after comparative testing of primary serum sam-
ples from all 280 household contacts, with one 
sample per person (Section 3 in the Supplementary 
Appendix). These combined studies suggested 
that a recombinant immunofluorescence assay 
would be an appropriate first-stage diagnostic 
test for seropositivity for ELISA-based screening 
results. A total of 6 household contacts had posi-
tive ELISA results and positive results on recom-
binant immunofluorescence assay, fulfilling the 
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definition of stage 1 seropositivity. These house-
hold contacts included none of those with posi-
tive results on RT-PCR. Serum from the RT-PCR–
positive contacts had been obtained 4 to 14 days 
after the onset of symptoms in the index pa-
tients, which suggested that these contacts were 
still in the period before seroconversion.
We asked all the household contacts for per-
mission to obtain a second blood sample after 
2 to 6 months for additional testing. Only 44 
contacts in nine clusters agreed to provide a 
second sample. Of these contacts, 5 had positive 
results on ELISA; of these 5 contacts, 2 were sero-
positive on recombinant immunofluorescence 
assays (stage 1 seropositivity) (Fig. 1C). One of 
these 2 contacts had stage 1 seropositivity on the 
basis of his first serum sample, and the other 
(Contact 180) underwent seroconversion some-
time between the first and second serum sample 
(Table S6 in the Supplementary Appendix).
Stage 2 seropositivity was tested on the basis 
of the above-mentioned PRNT cutoffs (PRNT90 
and PRNT50). PRNT90 titers were positive in an 
index patient (who was used as a control in the 
analysis of household contacts) and in samples 
obtained from 2 of 7 household contacts with 
stage 1 seropositivity. Three additional samples 
had positive PRNT50 titers (Table 2). To correlate 
serum neutralizing activities with specific anti-
body titers, we performed differential recombi-
nant immunofluorescence assays against all 
common HCoVs in all samples with confirmed 
stage 1 seropositivity  (Table 2). In the serum 
pair for Contact 180, results on differential re-
combinant immunofluorescence assay indicated 
a significant rise in titer against MERS-CoV but 
not against any of the other HCoVs tested. It was 
concluded that Contact 180 represented a spe-
cific MERS-CoV seroconversion. Since this sero-
conversion was detected on PRNT50 but not 
4 Positive PRNT
12 Probable cases of secondary
transmission
1 Positive PRNT
Stage 2
Seropositivity
7 Positive RT-PCR ORF1a
 6 Positive rIFA, full S  2 Positive rIFA, full S
Backup
Testing
Stage 1
Seropositivity
7 Positive RT-PCR upE 19 Positive rELISA S1 5 Positive rELISA S1Screening Screening
A 280 Pharyngeal Swabs B 280 Primary Serum Samples C 44 Follow-up Serum Samples
Figure 1. Diagnostic Testing Performed in the Study.
Throat swabs (column A) and serum samples (column B) were obtained from 280 household contacts of 26 index patients with MERS-
CoV infection. A total of 44 household contacts provided a second serum sample for follow-up (column C). Screening involved testing  
of all throat swabs by means of a reverse-transcriptase–polymerase-chain-reaction (RT-PCR) assay and testing of all serum samples by 
means of recombinant enzyme-linked immunosorbent assay (rELISA) with the use of the S1 domain of the MERS-CoV spike protein. RT-PCR 
backup testing was based on a second RT-PCR assay, including re-extraction from the original samples. Eluted RNA was screened for 
the MERS-CoV genomic region upstream of the envelope gene (upE) and within open reading frame (ORF) 1a. Testing for stage 1 sero-
positivity involved the use of recombinant immunofluorescence assay (rIFA) with the use of the full MERS-CoV spike protein (full S) for 
all serum samples with a positive result on ELISA screening. Testing for stage 2 seropositivity was performed on serum samples with 
stage 1 seropositivity by means of plaque-reduction neutralization testing (PRNT) with plaque reduction of 50% as the criterion for neu-
tralizing activity. Among the 4 samples with positive results on PRNT in column B, 2 were also determined to be positive on IgM testing. 
In the analysis of the 44 follow-up serum samples for stage 1 seropositivity, one case of MERS-CoV infection had already been confirmed 
in the primary serum sample, and one case was identified as a new seroconversion.
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PRNT90, we chose PRNT50 as a criterion to de-
fine stage 2 seropositivity in our diagnostic al-
gorithm. Application of this criterion resulted in 
the identification of 5 household contacts with 
stage 2 seropositivity.
Since it is unknown whether the development 
of neutralizing antibodies as measured on PRNT 
can lag behind the development of reactivity on 
ELISA and immunofluorescence assay, we evalu-
ated IgM antibodies as an additional potential 
indicator of recent infection. However, IgM titers 
were detected in serum samples that had posi-
tive PRNT90 titers but not in samples with iso-
lated PRNT50 titers, which suggests that testing 
for IgM antibodies in an immunofluorescence 
assay–based format provides low sensitivity over-
all (Table 2). Table 3 summarizes the final study 
results, including the results of testing of second 
serum samples when they were available.
Discussion
We report the results of a targeted investigation 
of silent and mild infections in the 280 house-
hold contacts of 26 index patients in whom 
MERS-CoV infection had been confirmed on 
RT-PCR assay with corroborating clinical find-
ings. Seven household contacts carried MERS-CoV 
in their upper respiratory tract, as shown on 
RT-PCR assays. Pharyngeal RNA concentrations 
were low in most contacts, a finding that match-
es observations in a study on SARS in Taiwan in 
which asymptomatic or mildly symptomatic 
health care workers were shown to carry low 
pharyngeal levels of viral RNA after exposure to 
patients infected with SARS-CoV.13 Our find-
ings suggest that young persons without coex-
isting illnesses may be able to carry low levels 
of MERS-CoV RNA without obvious symptoms. 
Table 1. Laboratory Data and History of 12 Household Contacts Identified as Having Probable Secondary Infection with MERS-CoV.*
Contact
No. Age Sex
Latency 
Period† Serologic Analysis
Results of RT-
PCR Assay‡ Symptoms
Coexisting 
Illnesses
Animal 
Contact
yr days
RNA copies/
sample
52 28 F 14 ELISA, 0.11 (negative); IFA, negative Positive§ None Unknown None
278 7 F 4 ELISA, 0.06 (negative); IFA, negative 38,500 None None Camels
279 15 M 4 ELISA, 0.10 (negative); IFA, negative 2700 None None Camels
280 26 M 4 ELISA, 0.07 (negative); IFA, negative 38,500 None None None
257 74 F 8 ELISA, 0.06 (negative); IFA, negative 80,000 Pharyngitis¶ None None
258 3 F 8 ELISA, 0.05 (negative); IFA, negative <500 None None None
259 18 M 8 ELISA, 0.07 (negative); IFA, negative <500 None None None
99 37 M 19 ELISA, 1.82 (reactive); IFA, 1:1280; 
PRNT, 1:160; IgM, 1:40
Negative None None None
104 24 M 19 ELISA, 1.84 (reactive); IFA, 1:2560; 
PRNT, 1:160; IgM, 1:40
Negative None None None
102 31 M 19 ELISA, 0.45 (reactive); IFA, 1:320; 
PRNT, 1:40; IgM, negative
Negative None Unknown None
180‖ 26 F 23 ELISA, 0.9 (reactive); IFA, 1:1280; 
PRNT, 1:40; IgM, negative
Negative None Unknown None
193 31 M 13 ELISA,1.57; (reactive); IFA, 1:40; 
PRNT, 1:40; IgM, negative
Negative None None None
* Secondary infection was defined as dual positivity on RT-PCR assay or stage 2 seropositivity. ELISA denotes enzyme-linked immunosorbent 
assay, F female, IFA immunofluorescence assay, M male, and PRNT plaque-reduction neutralization testing.
† The latency period was the number of days between the onset of symptoms in the index patient and sampling of the household contact.
‡ The result was based on positive outcome of two independent RT-PCR assays in the upE and ORF1a target genes after reextraction from the 
original sample. The approximate concentration is based on the upE target gene assay.
§ This sample was tested in a local laboratory by means of RT-PCR assays in the upE and ORF1a target genes without recording of values for 
the threshold cycle (RNA concentration unknown). The original sample was not retrievable.
¶ This symptom was recorded on the day of sampling. Respiratory failure and death occurred in this contact soon after testing.
‖ For this household contact, laboratory results are based on a second follow-up serum sample.
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Asymptomatic, RT-PCR–positive health care work-
ers were identified in a recent outbreak of MERS 
in Jeddah.
However, positive RT-PCR findings in persons 
with subclinical infection who are tested soon 
after exposure should be complemented by sero-
logic analysis. In three earlier cross-sectional 
serologic studies, none of the 3024 participants 
showed evidence of previous infection with 
MERS-CoV.1,14,15 In our study, the detection of 
antibodies was most likely due to our focus on 
household contacts of index patients. Differences 
in assay sensitivity may play an additional role. 
Our staged serologic algorithm is based on ear-
lier experience with current assays or their tech-
nical precursors6,8,12,14,16-20 and was developed as 
much as possible by a comparison of methods in 
the study samples available. Although validation 
of this algorithm will be necessary, our results 
suggest that ELISA is an appropriate screening 
assay and that recombinant immunofluorescence 
assay is an appropriate first-stage confirmatory 
test, owing to its higher specificity without an 
apparent substantial lack of sensitivity. Differential 
serologic testing by means of recombinant im-
munofluorescence assay cannot be used to rule 
out MERS-CoV infection, since anti–MERS-CoV 
titers did not always predominate in probable 
cases of secondary transmission. It is unknown 
whether MERS-CoV infection may cause a boost in 
preexisting titers against related HCoVs acquired 
earlier in life, such as is seen with many other 
infectious diseases. There are conserved regions 
between S proteins in MERS-CoV and those in 
various HCoVs that might explain the existence 
of cross-reactive serum antibodies (Fig. S2 in the 
Supplementary Appendix). Testing for stage 2 sero-
positivity will therefore have to rely on PRNT as 
long as no better information regarding anti-
body cross-reactivity between MERS and HCoVs 
is available. We consider PRNT to be the most 
specific test because of its reliance on function-
ality of measured antibodies, but we cannot rule 
out cross-reactivity for results obtained.
In our study population, we encountered house-
hold contacts in whom serum neutralizing activ-
ity became apparent only when we used a 50% 
reduction in the test virus as a more sensitive 
diagnostic criterion than 90% reduction. This 
suggests that neutralizing antibodies are pro-
duced at low levels and are potentially short-lived 
after mild or asymptomatic infection, which puts 
the predictive value of cross-sectional serologic 
studies in perspective if such studies are not 
specifically targeted at persons with recent ex-
posure.
Table 2. Differential Serologic and Neutralization Analyses for MERS and Other Coronaviruses in 7 Household Contacts with Stage 1 
Seropositivity and 1 Index Patient.*
Cluster
Contact 
No. ELISA IgG Titer on Recombinant IFA
IgM Titer on 
Recombinant 
IFA PRNT MERS†
MERS SARS OC43 HKU1 229E NL63 MERS PRNT90 PRNT50
F Index 
patient
4.05 5120 160 1,280 1,280 1280 320 160 40 160
J 99 1.82 1280 Negative 2,560 1,280 640 160 40 80 160
J 102 0.45 320 1280 5,120 5,120 640 1280 Negative <20 40
J 104 1.83 2560 640 20,480 20,480 1280 2560 40 40 160
RIII 180‡ 0.05 Negative Negative 2,560 640 1280 640 Negative <20 <20
180§ 0.90 1280 Negative 1,280 320 640 320 Negative <20 40
RIII 187‡ 0.31 80 Negative 1,280 1,280 640 1280 Negative <20 <20
187§ 0.29 160 Negative 1,280 640 640 640 Negative <20 <20
RIV 193 1.57 40 160 320 640 1280 640 Negative <20 40
TII 274 0.46 160 Negative 2,560 1,280 160 160 Negative <20 <20
* SARS denotes severe acute respiratory syndrome.
† Stage 2 seropositivity was tested by means of PRNT with cutoff values of 90% (PRNT90) and 50% (PRNT50). A titer of less than 1:20 indi-
cates a negative result.
‡ This sample was obtained on day 23.
§ This sample was obtained on day 178 during follow-up.
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An important limitation of our study was the 
low rate of household contacts from whom we 
could obtain a second blood sample. Although 
the first serologic investigation was obligatory, 
the participation in follow-up investigations was 
voluntary. The sentiment in Saudi Arabia at the 
time that we conducted the study was dominated 
by stigmatization of patients with MERS and dis-
crimination against affected families. There was 
a widespread belief that medical care facilities 
act as sources of infection, triggered by media 
reports focusing on hospital outbreaks, such as 
that in Al-Hasa.21 For the combination of these 
reasons, household contacts would widely refuse 
to participate in any research activity connected 
with MERS.
Because of the limited number of follow-up 
samples and the variable timing of contact-
cluster investigations, the timing of serologic 
testing after the onset of symptoms in the index 
patients might have influenced the diagnostic 
usefulness of the various tests that we used. 
Positive RT-PCR findings in our study were iden-
tified only during the first 14 days after expo-
sure, whereas stage 2 seropositivity was identified 
only 13 days or more after exposure (Table 1). 
This matches expected patterns of laboratory 
results when infections are acquired around the 
time of or shortly after exposure (defined as the 
time of symptom onset in index patients). In par-
ticular, the timing of the first antibody results 
for stage 2 seropositivity matches the typical 
Table 3. Summary of Serologic Results in Household Contacts, According to Timing of Sampling. *
Variable
Time from Onset of Symptoms in Index Patient  
until Sampling of Contact
Any Time <2 Wk 2–3 Wk >3 Wk†
No. of household contacts 280 127 45 108
No. of clusters 26 10 3 13
Positive results — no. (%)
RT-PCR 7 (2) 7 (6) 0 0
ELISA 20 (7) 8 (6) 3 (7) 11 (10)
IFA 7 (2) 1 (1) 3 (7) 3 (3)
IFA plus PRNT 5 (2) 1 (1) 3 (7) 1 (1)
Household contacts with possible or probable secondary 
infection — no. (%)
Possible on basis of RT-PCR or stage 1 seropositivity 14 (5) 8 (6)‡ 3 (7) 3 (3)
Positive RT-PCR assay 7 (2) 7 (6) 0 0
Stage 1 seropositivity 7 (2) 1 (1) 3 (7) 3 (3)
Probable on basis of dual positive RT-PCR assays or stage 2 
seropositivity
12 (4) 8 (6) 3 (7) 1 (1)
Dual positive RT-PCR assays 7 (2) 7 (6) 0 0
Stage 2 seropositivity 5 (2) 1 (1) 3 (7) 1 (1)
Clusters of household contacts with possible or probable 
secondary infection — no. (%)
Possible on basis of RT-PCR or stage 1 seropositivity‡ 6 (23) 4 (40) 1 (33) 2 (15)
Positive RT-PCR assay 3 (12) 3 (30) 0 0
Stage 1 seropositivity 4 (15) 1 (10) 1 (33) 2 (15)
Probable on basis of dual positive RT-PCR assays or stage 2 
seropositivity
6 (23) 4 (40) 1 (33) 1 (8)
Dual positive RT-PCR assays 3 (12) 3 (30) 0 0
Stage 2 seropositivity 3 (12) 1 (10) 1 (33) 1 (8)
* Percentages may not sum to the overall total in a category because of rounding.
† For household contacts who provided serum samples more than 3 weeks after exposure, the indicated test results are based on second sam-
ples if they were available.
‡ One cluster included a contact with positive results on RT-PCR and another with positive serologic results.
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timing for the development of an IgG response. 
If we had evaluated only household contacts who 
had provided serum samples 13 days or more 
after exposure and considered only serologic 
results, we would have identified cases of prob-
able transmission in 5 of 172 contacts (3%; 95% 
confidence interval [CI], 1 to 7) in 4 of 17 clus-
ters (24%). These data from limited testing are 
consistent with the overall study results on the 
basis of RT-PCR and serologic analysis (i.e., rates 
of secondary infection of 4% [95% CI, 2 to 7] 
among household contacts, in 23% of the clus-
ters). Therefore, although RT-PCR testing may 
have compensated for a lack of serologic follow-
up in household contacts who provided serum 
samples only during the first 2 weeks after ex-
posure, we cannot determine whether we may 
have missed contacts who had delayed serocon-
version. We also could not evaluate possible 
common sources of exposure for index patients 
and their household contacts.
Finally, it is relevant to note that in the whole 
study, we identified only 12 household contacts 
who may have been infected by 26 index cases. 
Although rates of secondary transmission may 
be higher in other situations, such as nosoco-
mial outbreaks or social circumstances in which 
there may be a more closed or intimate environ-
ment, these data may inform approaches to esti-
mating the epidemiologic reach of MERS-CoV in 
humans.3,4
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1 Technical assessment of serological methods 
	
The	MERS‐CoV	S1	domain	ELISA	has	been	developed	by	authors	M.A.M,	B.M.,	and	C.D.	
(University	of	Bonn)	in	collaboration	with	author	E.L.	at	Euroimmun	AG	as	a	ready‐to‐
use	diagnostic	reagent	set.	The	antigen	for	the	assay	is	provided	in	bulk	by	author	B.J.B.	
The	assay	includes	a	constant	serum	reference	(borderline‐reactive	human	serum	from	
a	German	patient	with	a	titer	against	HCoV‐OC43	but	not	MERS‐CoV	proven	by	rIFA)	
that	is	included	in	every	run	as	a	calibrator	of	the	upper	limit	of	the	reference	range	of	
non‐infected	persons	(cut‐off).	Results	are	provided	in	the	form	of	optical	density	(OD)	
ratios	as	a	relative	measure	for	the	concentration	of	antibodies.	Results	can	be	evaluated	
semi‐quantitatively	by	calculating	a	ratio	of	the	OD	of	the	test	sample	versus	that	of	the	
calibrator	(OD	ratio).	All	ELISA	results	given	in	this	article	are	expressed	as	OD	ratios.		
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As	part	of	the	assay	assessment	process	the	assay	was	tested	on	MERS‐CoV	antibody	
negative	sera	as	follows:	3	patients	with	high	antibody	titers	against	influenza	A	(based	
on	ELISA);	1	patient	with	high	titers	against	human	parainfluenzavirus	1	(based	on	
ELISA);	1	patient	with	high	titers	against	human	respiratory	syncytial	virus	type	A	
(based	on	ELISA);	2	patients	with	proven	titers	against	HCoV‐OC43	(based	on	rIFA);	one	
patient	with	acute	Mycoplasma	pneumoniae	infection	based	on	ELISA;	7	patients	with	
acute	Epstein	Barr	virus	infection	based	on	ELISA;	9	patients	with	antibody	titer	against	
SARS‐CoV	based	on	rIFA;	10	healthy	European	blood	donors;	10	healthy	children;	10	
healthy	pregnant	women.	Background	intertest	variability	was	studied	using	28	
determinations	of	reactivity	in	healthy	blood	donors.	All	of	these	control	materials	are	
being	stored	at	Euroimmun,	Lübeck/Germany	with	documentation	according	to	good	
manufacturing	practice.		
To	provide	an	impression	of	the	signal‐to‐noise	ratio	in	patients	investigated	in	the	
present	study,	Figure	S1	shows	the	OD	ratio	values	obtained	with	all	primary	serum	
samples	except	6	samples	from	the	first	blood	samplings,	as	well	as	all	44	follow‐up	
serum	samples.		
	
2 Additional information on contact subjects  
	
Information	on	underlying	diseases	was	recorded	on	the	basis	of	a	standardized	
questionnaire	for	178	contact	cases	(Supplementary	Table	S1).		
	
	
3 Auxiliary analyses to reach a serological strategy for contact 
testing 
	
The	 lack	 of	 reference	 samples	 to	 validate	 different	 serological	 methods	 requires	 a	
pragmatic	 approach	 to	 the	 interpretation	 of	 serological	 results.	 The	 following	 text	
describes	essential	analyses	and	considerations	behind	our	choice	of	criteria	for	defining	
stages	of	laboratory	evidence	of	infection.		
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3.1 IFA specificity and choice of IFA method for additional testing 
Initial	testing	of	280	sera	(first	bleedings)	yielded	19	sera	reactive	by	ELISA	and	six	sera	
reactive	by	rIFA.	While	 the	six	rIFA‐reactive	samples	were	congruent	with	19	samples	
reactive	 in	 ELISA,	 vIFA	 identified	 three	 additional	 reactive	 sera	 which	 where	 neither	
overlapping	ELISA	results	nor	reactive	by	NT	or	IgM.	Similar	results	had	been	obtained	
earlier	 using	 vIFA	 during	 contact	 tracing	 studies	 in	 Germany	 and	 a	 cross‐sectional	
serosurvey	 in	 Jeddah/KSA	 (Table	 S31,2).	 These	 were	 interpreted	 as	 cross‐reactive	 or	
nonspecific	 titers	 in	 earlier	 studies.	 To	 determine	 titers	 against	 common	 HCoV,	
differential	rIFA	was	used	under	a	protocol	that	involves	screening	of	serum	at	dilutions	
1:100	 and	 1:1000	 instead	 of	 full	 Log2	 titration.	 The	 results	 for	 those	 three	 sera	 that	
tested	 positive	 only	 by	 vIFA	 are	 shown	 in	 Table	 S2,	 suggesting	 the	 presence	 of	
dominant	 titers	 against	 common	 HCoVs	 other	 than	 MERS‐CoV	 in	 these	 sera.	 For	
reference	we	summarize	the	results	from	our	earlier	studies	in	Table	S3.	Overall	these	
results	 document	 the	 limited	 specificity	 of	 vIFA.	 rIFA	 was	 therefore	 used	 for	 further	
studies.	
	
3.2 Additional testing  
To	decide	whether	ELISA	results	should	be	tested	by	rIFA	we	relied	on	the	assumption	
that	true	positive	cases	should	have	developed	antibodies	following	recent	contact	with	
an	 index	 case.	We	 therefore	determined	whether	 time	 since	 exposure	 correlated	with	
rates	of	antibody	results	in	contacts	(Table	S4).	Day	of	onset	of	symptoms	in	index	cases	
was	 defined	 as	 the	 first	 day	 of	 exposure.	 Data	 and	 samples	 for	 this	 validation	 were	
available	 for	N	=	268	 contact	 subjects.	As	 shown	 in	 the	 table,	 Chi‐square	 and	Fisher´s	
exact	 tests	 did	 not	 reject	 the	 assumption	 that	 positive	 results	were	more	 frequent	 in	
samples	 taken	 after	 >14	 days	 post	 exposure,	 if	 based	 on	 ELISA	 only.	 However,	 this	
assumption	was	rejected	by	both	tests	if	the	definition	of	positive	samples	was	based	on	
a	 combination	 of	 ELISA	 and	 rIFA	 results.	 It	 should	 be	 noted	 that	 for	 the	 given	 set	 of	
samples	 rIFA	 tests	 alone	 would	 have	 led	 to	 the	 same	 outcome,	 as	 no	 sample	 tested	
positive	by	rIFA	and	negative	by	ELISA.	However,	ELISA	is	considerably	easier	to	handle	
and	compatible	with	high‐throughput	 screening.	Our	diagnostic	 strategy	based	on	our	
current	knowledge	 therefore	 consists	of	 a	 sequential	 approach	 including	 screening	by	
ELISA	and	positive	testing	by	rIFA.		
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3.3 Sensitivity of ELISA and rIFA 
Because	 14	 sera	 reacted	 by	 ELISA	 but	 not	 by	 rIFA	 (13	 in	 the	 first	 sampling	 of	 280	
subjects,	 1	 in	 the	 second	 sampling	 of	 44	 subjects),	 we	 determined	 whether	 these	
samples	had	concomitant	titers	against	common	HCoV.	Differential	rIFA	was	 therefore	
done	like	above.	The	results	for	all	14	sera	as	shown	in	Table	S5	confirm	the	presence	of	
titers	against	common	HCoVs	other	than	MERS‐CoV	in	all	sera.	However,	further	studies	
will	be	necessary	to	determine	whether	antibodies	against	HCoV	cross‐react	with	MERS‐
CoV.		
	
In	 spite	 this	 analysis	 suggested	 the	 excess	 of	 ELISA‐positive	 samples	 to	 be	 a	 result	 of	
lack	of	specificity	in	ELISA	rather	than	superior	sensitivity	over	rIFA,	 it	was	difficult	to	
compare	sensitivity	directly	because	this	would	require	serum	panels	taken	sequentially	
during	seroconversion	on	different	patients.	For	the	purpose	of	this	study,	we	could	only	
use	those	serum	pairs	(of	44	in	total)	in	which	a	positive	ELISA	result	was	obtained	in	
the	second	bleeding	sample.	Table	S6	summarizes	all	five	serum	pairs	in	which	this	was	
the	case.	Because	the	ELISA	used	in	these	studies	is	calibrated	against	a	reference	serum,	
and	 because	 the	 OD	 values	 in	 all	 samples	 are	 below	 0.5	 suggesting	 no	 saturation	 of	
signal,	it	was	assumed	that	ELISA	ratio	values	are	approximately	proportional	to	titers.	
Consequently,	 it	was	 assumed	 that	 a	 significant	 increase	 in	 titer	 over	 the	 observation	
period	should	 involve	an	 increase	 in	ELISA	 ratio	 signal	by	>4	 fold.	This	 condition	was	
only	fulfilled	by	one	of	five	serum	pairs	(No	180	marked	with	an	asterisk).	This	serum	
pair	 showed	 a	 strong	 IFA	 titer	 in	 the	 second	 sample.	 Another	 serum	 pair	 (No	 187)	
showed	 a	 constant	 titer	 in	 ELISA	 and	 IFA	 which	 is	 compatible	 with	 non‐recent	
seroconversion.	One	serum	(No	211)	had	a	decreasing	ELISA	titer,	matching	the	absence	
of	any	signal	detectable	by	IFA.	 In	summary,	these	results	suggest	that	IFA	may	detect	
significant	 rises	 in	 antibody	 titers	 in	 contact	 cases	 even	 if	 not	 triggered	by	MERS‐CoV	
specifically.	
	
3.4 Technical considerations regarding neutralization assay format 
Virus	neutralization	test	(NT)	is	based	on	co‐incubation	of	patient	serum	with	a	seed	
dose	of	virus	in	the	range	of	50	to	100	infectious	units	(plaque	forming	units)	followed	
by	subsequent	infection	in	cell	culture.	In	the	context	of	this	study	we	were	interested	to	
apply	a	highly	sensitive	version	of	NT.	Sensitivity	can	be	increased	by	reducing	the	virus	
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seed	dose.	However,	seed	dose	should	not	be	decreased	below	50	infectious	units	to	
avoid	variation	due	to	poisson	distribution	effects.	We	therefore	chose	a	version	of	NT	
which	relies	on	plaque	assay	cell	culture	read	out	wherein	the	cell	monolayers	used	to	
detect	remaining	infectious	virus	after	serum	co‐incubation	are	overlaid	with	a	diffusion	
barrier	medium	that	reveals	infection	events	caused	by	individual	infectious	virus	
particles	contained	in	the	seed	dose.	This	assay	format	enabled	us	to	determine	the	
antibody	titer	that	was	capable	of	reducing	the	infectious	virus	seed	dose	by	50%	and	by	
90%,	instead	of	100%	reduction	as	in	a	normal	NT.	The	50%	and	90%	plaque	reduction	
neutralization	titers	are	referenced	as	PRNT50	and	PRNT90.	As	the	entry	dilution	in	these	
titrations	was	1:10,	titers	equal	or	greater	than	1:20	were	counted	as	significant.	Results	
of	comparative	testing	are	summarized	in	the	main	text,	Table	2.		
	
4 Supplementary Figures  
	
4.1 Figure S1 
	
Figure	S1.	ELISA	Cutoff	in	relation	to	actual	OD	ratios	in	274	sera	from	contact	
subjects	(first	collection)	and	all	44	sera	in	the	second	collection.	Sere	were	pre‐
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diluted	1:100.	Optical	densities	(OD)	were	measured	at	450	nm.	Ratios	were	determined	
by	dividing	individual	OD	values	with	a	calibrator	serum	used	in	all	rELISA	tests.			
	
4.2 Figure S2 
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MERS       604 VEYSLYGVSGRGVFQNCTAVGVRQQR-FVYDAYQNLVGYYSDDG-NYYCLRACVSVPVSVIYDKETKTHATLFGSVACEHISSTMSQYSRSTRSMLKRRD 
OC43       630 VNYDLYGILGQGIFVEVNATYYNSWQNLLYDSNGNLYGFRDYITNRTFMIRSCYSGRVSAAFHANSSEPALLFRNIKCNYVFNNS----------LTRQL 
HKU1       622 VDYDLYGITGQGIFKEVSAVYYNSWQNLLYDSNGNIIGFKDFVTNKTYNIFPCYAGRVSAAFHQNASSLALLYRNLKCSYVLNN-------------ISL 
229E       447 TKYNIYDVSGVGVIRVSNDTFLNGIT--YTSTSGNLLGFKDVTKGTIYSITPCNPPDQLVVYQQAVVGAMLSEN--FTSYGFSN---------------- 
NL63       628 TKYNIYDYVGTGIIRSSNQSLAGGIT--YVSNSGNLLGFKNVSTGNIFIVTPCNQPDQVAVYQQSIIGAMTAVN--ESRYGLQN---------------- 
consensus  701 . * .*...* *...  .... .     .... .*..*...  .   . . .*    ..... .     ....  . . .. ..                 
 
 
MERS       702 STYGPLQTPVGCVLGLVN-SSLFVEDCKLPLGQSLCALP----DTPSTLTPR 
OC43       720 QPINYFDSYLGCVVNAYNSTAISVQTCDLTVGSGYCVDY-----SKNRRSRG 
HKU1       709 TTQPYFDSYLGCVFNADNLTDYSVSSCALRMGSGFCVDYNSPSSSSSRRKRR 
229E       527 ------VVELPKFFYASNGTYNCTDAVLTYSSFGVCADG------------S  
NL63       708 ------LLQLPNFYYVSNGGNNCTTAVMTYSNFGICADG------------S  
consensus  801        . ..... . * .   .  . . .. ..*..      .        
 
 
 
Figure	S2	Protein	sequence	alignment	of	the	Spike	S1	subunits	of	MERS‐CoV	
(residues	1‐747),	HCoV‐OC43	(residues	1‐766),	HKU1	(residues	1‐760),	HCoV‐229E	
(residues	1‐560)	and	HCoV‐NL63	(residues	1‐741)(NCBI	Reference	Sequences:	
	 	 	 	7
AFS88936.1,	NP_937950.1,	YP_173238.1,	NP_073551.1	and	YP_003767.1,	respectively).	
Multiple	sequence	alignment	was	performed	with	ClustalO	and	visualized	with	
BoxShade.	Identical	and	similar	residues	are	indicated	with	an	asterisk	or	dot,	
respectively.	
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5 Supplementary Tables 
	
	
5.1 Table S1. Comorbidities in 178 of 280 studied subjects 
	
Comorbidities	 Number %
Asthma	 6 3.4
Diabetes	 6 3.4
Arterial	hypertension	 1 0.6
Arterial	hypertension,	Diabetes	 5 2.8
Arterial	hypertension,	Heart	disease 2 1.1
Arterial	hypertension,	Sickle	cell	anemia 2 1.1
None	 156 87.6
Total	 178 100
	
	
5.2 Table S2. Differential rIFA assays for three sera reactive in MERS‐CoV 
vIFA but not rIFA 
	
Subject ID  Serum dilution  229E‐S HKU1‐S MERS‐S NL63‐S OC43‐S  SARS‐S 
2  1:100  reactive reactive neg.  reactive reactive  neg. 
  1:1000  neg. neg. neg. neg. reactive  neg. 
58  1:100  reactive reactive neg.  neg.  reactive  neg. 
  1:1000  neg.  neg.  neg.  neg.  neg.  neg. 
107  1:100  reactive reactive neg.  neg.  reactive  neg. 
  1:1000  neg. neg. neg. neg. neg. neg. 
	
	
	
5.3 Table S3. Summary of results of vIFA and rIFA testing in 2 earlier studies 
	
Confirmatory	assay
Study	 vIFA	 rIFA	 NT	 Reference	
Slaughterhouse	
study	KSA	 8/356	(2.2%)	 0/8	 0/8	 1	
Case	contact	study	
Essen,	Germany	 2/85	(2.4%)	 0/2	 0/2	 2	
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5.4 Table S4. Rates of positive results by ELISA and rIFA versus time since 
exposure 
	
Time	since	
exposure	
ELISA	only	
(N	reactive/	N	neg.)	 Statistical	test	
ELISA	and	IFA	combined*	
(N	reactive/	N	neg.)	 Statistical	test	
<14	days	 8/148	 Chi2=1.5;	p>0.12	
Fisher´s	exact,	p>0.16	
1/148 Chi2=4.3;	p<0.018	
Fisher´s	exact,	p<0.048	>14	days	 10/102	 5/102
*in	the	dataset,	this	combination	of	results	is	equal	to	IFA	results	only.		
	
	
	
5.5 Table S5. Differential rIFAs in all 14 samples reactive by ELISA but not 
rIFA 
	
Subject ID  Serum Dilution  229E‐S  HKU1‐S  MERS‐S  NL63‐S  OC43‐S  SARS‐S 
3  1:100 reactive  neg. neg. reactive reactive  neg.
  1:1000  neg.  neg.  neg.  neg.  neg.  neg. 
44  1:100  neg.  reactive  neg.  reactive  reactive  neg. 
  1:1000  neg.  neg.  neg.  neg.  neg.  neg. 
94  1:100 reactive  reactive neg. reactive reactive  neg.
  1:1000  neg.  neg.  neg.  neg.  reactive  neg. 
161  1:100  reactive  reactive  neg.  neg.  reactive  neg. 
  1:1000  neg.  neg.  neg.  neg.  reactive  neg. 
174  1:100 reactive  reactive neg. neg. reactive  neg.
  1:1000  neg.  neg.  neg.  neg.  reactive  neg. 
185  1:100  reactive  reactive  neg.  reactive  reactive  neg. 
  1:1000  reactive  neg.  neg.  neg.  reactive  neg. 
207  1:100 reactive  reactive neg. reactive reactive  neg.
  1:1000  neg.  neg.  neg.  neg.  reactive  neg. 
211  1:100  reactive  reactive  neg.  reactive  reactive  neg. 
  1:1000  neg.  neg.  neg.  neg.  neg.  neg. 
217  1:100 pos  reactive neg. reactive reactive  neg.
  1:1000  neg.  neg.  neg.  neg.  neg.  neg. 
225  1:100  reactive  reactive  neg.  reactive  reactive  neg. 
  1:1000  reactive  neg.  neg.  neg.  reactive  neg. 
229  1:100 neg.  reactive neg. reactive reactive  neg.
  1:1000  neg.  neg.  neg.  neg.  neg.  neg. 
249  1:100  reactive  reactive  neg.  neg.  reactive  neg. 
  1:1000  neg.  neg.  neg.  neg.  reactive  neg. 
106  1:100 reactive  reactive neg. reactive reactive  neg.
  1:1000  neg.  neg. neg. neg. reactive  neg.
39  1:100  reactive  reactive  neg.  reactive  reactive  neg. 
  1:1000  neg.  neg.  neg.  neg.  reactive  neg. 
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5.6 Table S6. Summary of test results selected in serum pairs 
	
Case	 Time	since	exposure	
ELISA	
1st	
serum	
ELISA	
2nd	
serum	
IFA	1st	
serum	
IFA	2nd	
serum	
Latency	1st	to	
2nd	serum	
(days)	
NT	any	
serum	
OD	ratio	
increase	
39	 13	 0.14	 0.21	 neg	 neg	 73	 neg	 no	
180*	 13	 0.05	 0.9	 neg	 1280	 155	 neg	 yes	
187	 23	 0.31	 0.29	 80	 160	 155	 neg	 no	
211	 23	 0.78	 0.39	 neg	 neg	 104	 neg	 no	
229	 11	 0.28	 0.53	 neg	 neg	 120	 neg	 no	
		
*>4‐fold	increase	of	ELISA	ratio	in	paired	sera.	Highest	titers	in	rIFA	against	HCoV‐OC43	
and	MERS‐CoV.	MERS‐CoV	NT	negative.			
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